Clinical Trial Update: IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing IBI363 to docetaxel in advanced squamous non-small cell lung cancer after standard treatments have failed is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• IBI363

Snippet

Sponsor: Fortvita Biologics (USA)Inc. | Conditions: iO Resistant sqNSCLC | Phase 3 | Status: RECRUITING